Avidity biosciences reports second quarter 2021 financial results and recent highlights

La jolla, calif., aug. 9, 2021 /prnewswire/ -- avidity biosciences, inc. (nasdaq: rna), a biopharmaceutical company committed to delivering a new class of rna therapeutics called antibody oligonucleotide conjugates (aocs™), today reported financial results for the second quarter and six months ended june 30, 2021 and highlighted recent corporate progress.
RNA Ratings Summary
RNA Quant Ranking